Poolbeg Pharma PLC - Clinical-stage biopharmaceutical company targeting diseases with a high unmet medical need - Appoints a number of former executives of Amryt Pharma PLC to its leadership team. Poolbeg's Chair, Cathal Friel, co-founded both Poolbeg and Amryt Pharma. Read More
(Alliance News) - Poolbeg Pharma PLC on Tuesday said it has agreed to collaborate with an unnamed Nasdaq-listed biopharmaceutical company for the development of an optimised oral drug to treat a metabolic condition. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued last week and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday, Thursday and Wednesday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of earnings of London-listed companies, issued on Wednesday and not separately reported by Alliance News: Read More
(Alliance News) - Poolbeg Pharma PLC on Thursday said it has made a significant breakthrough in its "world-first" influenza artificial intelligence programme with CytoReason Ltd. Read More
Poolbeg Pharma PLC - London-based infectious disease focused biopharmaceutical company - Says oral vaccine programme is moving forward to encapsulation validation process. Expects validation to be completed in the second half of 2023. Back in November, Poolbeg's consortium EncOvac received funding of EUR2.3 million from the Irish government to improve the manufacturing, distribution and administration of its oral vaccines. Poolbeg is collaborating with University College Dublin, Trinity College Dublin and AnaBio Technologies over three years to develop an oral vaccine candidate to a phase 1 ready state. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and Tuesday not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More
(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Thursday. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News: Read More
(Alliance News) - Poolbeg Pharma PLC on Monday said initial data analysis in its POLB 001 LPS challenge trial indicated a clear anti-inflammatory response. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued this week and not separately reported by Alliance News: Read More
(Alliance News) - Poolbeg Pharma PLC on Tuesday said it has received funding from the Irish Government to improve the manufacturing, distribution and administration of its oral vaccines. Read More
Poolbeg Pharma PLC - London-based clinical stage infectious disease pharmaceutical company - Announces "significant breakthrough" in its artificial intelligence programme with its partner OneThree Biotech Inc, a New York-based drug discovery-focused firm. Says breakthrough is the discovery of novel drug targets for the treatment of respiratory syncytial virus. The identification of these targets allow for the final stages of the programme to start, Poolbeg explains. This will involve the identification of small molecule inhibitors to treat RSV infections. The team is "particularly excited", the firm says, as these include a range of targets for which there are known drugs with existing Phase I safety and tolerability data. Results are expected before the end of 2022. Read More
(Alliance News) - Poolbeg Pharma PLC on Tuesday said that the US Patent & Trademarks Office has indicated that its patent application concerning the use of POLB 001 and its homologues for the treatment of hypercytokinemia is allowable. Read More